Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

ending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

Amicus continued to make progress throughout the fourth quarter with its ongoing Phase 2 clinical trial of AT2220 in adult Pompe patients. The trial includes an 11-week treatment period with an optional extension study. The objectives of the trial include the evaluation of the safety and pharmacodynamics of multiple doses and regimens of AT2220. The results of this study are expected to be available in the second half of 2009.

In addition, Amicus is continuing to conduct preclinical animal studies to evaluate the effects of administering AT2220 in combination with ERT. Results announced at the American Society of Human Genetics conference in November 2008 indicate that AT2220 in combination with ERT has the potential to increase the stability and tissue uptake of ERT. Amicus is conducting additional preclinical proof-of-concept studies to determine the feasibility of a combination that may be appropriate for Pompe patients who are not amenable to chaperone monotherapy. Amicus expects to discuss additional results at relevant scientific conferences during 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research and development to assess the potential for applying its versatile chaperone technology platform to the treatment of a broader range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

2009 Financial Guidance

In 2009, Amicus expects to report approximately $70 million in operating expenses, which it expects to be offset by approximately $50 million in program cost-sharing reimbursements and clinical mil
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 ITRA Global, ... and occupiers of commercial real estate, has further expanded ... offices in Perth and Brisbane, Western Australia, reports Mylinda ... directors. , ITRA Global / ACORPP (Australian Corporate ... independent consultancy company providing property services to a wide ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... FL (PRWEB) December 18, 2014 ... the nation’s leading specialty pharmacies, has an expanded ... as clinical pharmacy consultants for prescriber offices in ... expertise. , “We have a variety of ... For example, those specializing in hepatitis C help ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... 4 Pfizer,s loss of some top,talent, including ... of two,Michigan companies teaming to help speed research ... bone disease, rheumatoid arthritis and,osteoporosis., Velcura Therapeutics ... biotechnology company will work with Dr. Sliskovic and ...
... Support For Cutting-Edge Health Research Will Create Jobs, Attract ... ... /PRNewswire/ - The Ontario government is providing $150,million through the Next ... Minister of Research and,Innovation John Wilkinson has announced., "Attracting these ...
... of Cancer and Women,s Health to Assist Company in ... ... Needs, REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February ... its Medical Advisory Board. Rosetta Genomics has,assembled world-leading clinicians in ...
Cached Biology Technology:Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2Sparking Growth In Ontario's Biopharmaceutical Industry 2Sparking Growth In Ontario's Biopharmaceutical Industry 3Rosetta Genomics Establishes Medical Advisory Board 2Rosetta Genomics Establishes Medical Advisory Board 3Rosetta Genomics Establishes Medical Advisory Board 4Rosetta Genomics Establishes Medical Advisory Board 5
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... can transmit Lyme disease from host animals to humans, ... when spending time outdoors. University of Illinois ... black-legged ticks (also known as deer ticks), their host ... and Piatt Counties. The survey confirmed the presence ...
... RIVERSIDE, Calif. ( www.ucr.edu ) -- A year ago, ... engineering at the UC Riverside Bourns College of Engineering, ... to study water quality and sustainability issues in a ... a a deep familiarity with Skype, a baby daughter ...
... N.C. -- As physician-guided robots routinely operate on patients ... eliminate a surprising element from that scenario -- the ... have demonstrated that a robot -- without any human ... in simulated human organs, guide a device to the ...
Cached Biology News:Research results confirm need for protection against ticks that carry Lyme disease 2Research results confirm need for protection against ticks that carry Lyme disease 3A baby, Skype and water research partnership with Israel 2A baby, Skype and water research partnership with Israel 3Next generation surgical robots: Where's the doctor? 2Next generation surgical robots: Where's the doctor? 3